The following message was updated on 11/28/2022 3:06:17 PM.
V-Go Should Do 2 Things for MNKD's Revenue and Profitability
First, it should make the Endocrine Group's national sales force more productive, with the offering of a second product, aimed exclusively at Type II diabetics. Second, if V-Go's sales and manufacturing volume can be upscaled (and automated), it should also allow its gross margin to improve considerably. JMHO, with the input coming from the MNKD third quarter conference call.
